Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Technology Stocks : Stock Swap -- Ignore unavailable to you. Want to Upgrade?

To: Tech Master who wrote (12161)	2/18/1998 2:30:00 PM
From: Andrew Vance	Read Replies (3) \| Respond to of 17305

AV--For what it is worth, the list of hospital's mentioned in this release are quite prestigious. The experiments were conducted at the Montefiore Medical Center in New York City. Cheung Laboratories, Inc. is a research and development company dedicated to commercializing medical treatment systems for cancer and benign prostate hyperplasia (BPH) utilizing deep focused heat delivered by patented microwave technology. Cheung is presently working with Massachusetts General Hospital (MGH), Memorial Sloan-Kettering Hospital, Duke University, Oxford's Hammersmith Hospital, and others to develop its focused heat treatments. Unfortunately, I have had a great deal of interaction with most of the hospital's on this list years ago. All were involved in cancer treatments and research. A great deal of experimental work was being done there. As a matter of fact, my father was one of the experimental patients at Sloan-Kettering in the early 70's when Prednisone was being used as part of chemotherapy. They did a great deal failed human experimentation. The bad news is the word "experimental" treatments. Experimental work done by CGLB at these hospitals does not guarantee a successful future for the company. However, the good news is, that success here will spread rapidly through the medical community such that a medical success would in all likely result in a good commercial success for CGLB. The Company plans to file an Investigational Device Exemption (IDE) with the U.S. Food and Drug Administration (FDA) immediately. Receipt of the IDE will allow Cheung Laboratories to begin clinical trials on patients using its patented BPH treatment in order to obtain the necessary safety and efficacy data for FDA approval. Bottom Line: This is out of my field of expertise and competence but I will provide a comment. With the high percentage of men over 50 yrs old that could benefit from this technology, broad implementation could come down the road. The timing of the FDA approval cycle is an unknown to me and could drag on. With all this said, there is enough to this company from what you present and from what I found elsewhere that a modest investment for the long term is justified. A quick pop in price is going to be newsletter, hype, spam, SI thread, institutional coverage, takeover rumor, etal. driven. Herd mentality could drive this company up prior to financial performance. If it does, so what. The name of the game is to make money<GGG>. Andrew